Eversept Partners LP Makes New $2.36 Million Investment in Lipocine Inc. $LPCN

Eversept Partners LP bought a new stake in shares of Lipocine Inc. (NASDAQ:LPCN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 294,989 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,357,000. Eversept Partners LP owned approximately 3.58% of Lipocine as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of LPCN. Squadron Capital Management LLC purchased a new stake in shares of Lipocine in the fourth quarter worth about $4,256,000. Diadema Partners LP purchased a new position in Lipocine during the fourth quarter valued at approximately $2,095,000. AIGH Capital Management LLC purchased a new position in Lipocine during the first quarter valued at approximately $1,598,000. Ikarian Capital LLC bought a new stake in Lipocine during the 4th quarter worth approximately $1,602,000. Finally, Persistent Asset Partners Ltd bought a new stake in Lipocine during the 4th quarter worth approximately $567,000. 9.11% of the stock is currently owned by institutional investors.

Lipocine Trading Up 2.9%

LPCN stock opened at $2.14 on Tuesday. The company’s 50 day moving average is $2.29 and its 200 day moving average is $5.10. The stock has a market cap of $17.63 million, a price-to-earnings ratio of -1.14 and a beta of 0.44. Lipocine Inc. has a 1-year low of $1.81 and a 1-year high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.16 million. As a group, sell-side analysts forecast that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LPCN has been the subject of a number of recent analyst reports. HC Wainwright restated a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.00.

Lipocine Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.